Navigation Links
Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions
Date:5/25/2011

THOUSAND OAKS, Calif. and NEW YORK, May 25, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (PsO), and psoriatic arthritis (PsA), will be published at two global medical congresses, the European League Against Rheumatism (EULAR) and World Congress of Dermatology (WCD), this week.

"The breadth of data being presented at these congresses underscores our ongoing commitment to the rigorous study of these conditions where treatment has been shown to improve patient outcomes," said Yvonne Greenstreet, senior vice president and head of the Medicines Development Group for Pfizer's Specialty Care Business Unit. "With its first approval for RA in 1998, ENBREL has 2.5 million patient-years of collective clinical experience, and we continue to gain important knowledge about these conditions and the potential benefits of treating patients with certain chronic inflammatory diseases."

Selected abstracts of interest include:

Rheumatoid ArthritisImpact of Etanercept-Methotrexate (MTX) Therapy on Disease Activity and Radiographic Progression in Moderately Active Rheumatoid Arthritis: Interim Results of the PRESERVE Trial Persistent inflammation and associated joint damage may play a critical role in causing impairment in joint function in RA. Previous studies exploring treatment with biologics focused primarily on patients with severe disease. The radiographic data are an exploratory end
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
6. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Investor-Edge has initiated ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,419.48, up 2.40%, the ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014   ... a world-renowned leader in the field of infertility, ... approach to embryonic screening. The research abstract, released ... for Reproductive Medicine (ASRM) meeting in ... (CCS) and single gene defect (SGD) pre-implantation genetic ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... Choosing the right doctor when opting for cosmetic procedures ... subsequent costs often become determining factors rather than the ... on the right questions to ask and often times ... treatment. However, Board Certified Dermatologists can offer a skilled, ...
... N.J., Sept. 16, 2011 Novartis announced today positive ... ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), ... presented at the 2011 European Pediatric Rheumatology Congress in ... the study were met[2]. Most ACZ885 patients ...
Cached Medicine Technology:Trust Your Derm: The JUVA Skin & Laser Center Advises Patients To Seek Board Certified Dermatologists and AAAHC Accredited Facilities For Safe Cosmetic Procedures 2Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 2Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 3Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 4Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 5Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis 6
(Date:10/25/2014)... Hartford, CT (PRWEB) October 25, 2014 Background: ... for Addiction Recovery (CCAR). He is a pioneer in the ... 30-year career in Connecticut's state treatment system and when he ... had nagged him while in public service. ... are making critical decisions concerning them? , 2. Can ...
(Date:10/25/2014)... TX (PRWEB) October 25, 2014 ... Chinese Molecular Diagnostics Industry, 2009-2019 is a ... and Chinese Molecular Diagnostics industry. The report ... Diagnostics including its classification, application and manufacturing ... China’s top manufacturers of Molecular Diagnostics listing ...
(Date:10/25/2014)... 2014 The federal judge overseeing ... ) filed against Boston Scientific Corp. in the ... Southern District of West Virginia has denied a ... in a group of cases filed on behalf ... October 21st, U.S. District Judge Joseph R. Goodwin ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply to ... reduce the risks associated with the surgery, according to a ... stop the blood supply to the heart to be able ... the heart will reduce its ability to produce energy because ... flow to another large muscle, such as an arm or ...
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- Researchers who discovered ... findings are cause for concern. The use ... raised for human consumption contribute to the development ... to background information from the study. Each ... about 2 million people and kill about 23,000, ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2
... , CHICAGO , Jan. 26 ... a urologist tendered his $1-million insurance policy on January 20, ... deceased man arising out of the physician,s failure to timely diagnose bladder cancer. ... (Case no. 06 L 3887), Carmen Russell and Daniel Russell, ...
... , LITTLE FALLS, N.J. , ... provider of real-time, 24/7 medical news coverage and Continuing Medical ... from the American Academy of Family Physicians (AAFP) to offer ... physicians must have a broad understanding of many different diseases ...
... Jan. 26 President Obama will need several props ... including lifejackets, a box of teabags, a paper shredder, and a ... the address by taking the 2,074 page Senate health bill and ... the public a 20-page bill in plain, honest English," says ...
... January 26, 2010-- It,s known that people who live or ... die from serious injuries compared to those in more urban ... these higher mortality rates, new research suggests that limited access ... may be a factor. Researchers from St. Michael,s in ...
... recent case study by doctors at Mount Sinai Hospital ... transplant tourism, an offshoot of medical tourism, which focuses ... frown on the practice of transplant tourism where patients ... Philippines for their transplantation. These transplant tourists may ...
... ... ... National Heart Month, and Oldways and the Mediterranean Foods Alliance offer ... the Mediterranean region. Thousands of scientific studies (and the American Heart Association!) declare the Mediterranean ...
Cached Medicine News:Health News:Romanucci & Blandin, LLC, Reaches $1 Million Settlement in Medical Negligence Lawsuit 2Health News:MedPage Today(R) Approved to Offer AAFP Credit for Its News-Based Continuing Medical Education Activities 2Health News:MedPage Today(R) Approved to Offer AAFP Credit for Its News-Based Continuing Medical Education Activities 3Health News:Props for the President at His State of the Union Address 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 2Health News:More than 50 percent of injury-related deaths in rural Ontario occur before patients reach hospital 3Health News:Transplant tourism poses ethical dilemma for US doctors 2Health News:Transplant tourism poses ethical dilemma for US doctors 3Health News:10 Healthy Med Ways to Show Your Heart Some Love 2Health News:10 Healthy Med Ways to Show Your Heart Some Love 3
A versatile plate washer and/or dispenser that aspirates from the top down without immersing the aspirating tubes in the well, ensuring overflow protection. 5 programmable protocols....
The 96 PW is an intelligent full microplate washer with a 96 needle wash head washing all wells simultaneously. This instrument gives high throughput and outstanding washing efficiency....
The Finstrip combines high performance and flexibility with reliability, simplicity and ease of use....
Stat Fax 2600 is fully automatic microplate washer....
Medicine Products: